A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia

被引：17

作者：

Iwanaga, Eisaku ^{[1
]}

Nanri, Tomoko ^{[1
]}

Matsuno, Naofumi ^{[1
]}

Kawakita, Toshiro ^{[1
]}

Mitsuya, Hiroaki ^{[1
]}

Asou, Norio ^{[1
]}

机构：

[1] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 8608556, Japan

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 03期

关键词：

PROGNOSTIC IMPACT; JAK2; THERAPY;

D O I：

10.3324/haematol.13283

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：433 / 435

页数：3

共 12 条

[1] The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications [J].

Asou, N .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 45 (02) :129-150

[2] Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study [J].

Cairoli, R ;

Beghini, A ;

Grillo, G ;

Nadali, G ;

Elice, F ;

Ripamonti, CB ;

Colapietro, P ;

Nichelatti, M ;

Pezzetti, L ;

Lunghi, M ;

Cuneo, A ;

Viola, A ;

Ferrara, F ;

Lazzarino, M ;

Rodeghiero, F ;

Pizzolo, G ;

Larizza, L ;

Morra, E .

BLOOD, 2006, 107 (09) :3463-3468

[3]

Döhner K, 2006, HAEMATOLOGICA, V91, P1569

[4] JAK2V617F mutation in platelets from essential thrombocythemia patients:: correlation with clinical features and analysis of STAT5 phosphorylation status [J].

Heller, Paula G. ;

Lev, Paola R. ;

Salim, Juan P. ;

Kornblihtt, Laura I. ;

Goette, Nora P. ;

Chazarreta, Carlos D. ;

Glembotsky, Ana C. ;

Vassallu, Patricia S. ;

Marta, Rosana F. ;

Molinas, Felisa C. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (03) :210-216

[5] Jak2: normal function and role in hematopoietic disorders [J].

Ihle, James N. ;

Gilliland, D. Gary .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2007, 17 (01) :8-14

[6] Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias [J].

Illmer, Thomas ;

Schaich, Markus ;

Ehniger, Gerhard ;

Thiede, Christian .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01) :137-138

[7] Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO [J].

Kuchenbauer, F. ;

Schnittger, S. ;

Look, T. ;

Gilliland, G. ;

Tenen, D. ;

Haferlach, T. ;

Hiddemann, W. ;

Buske, C. ;

Schoch, C. .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (06) :616-619

[8] The JAK2 V617F mutation in de novo acute myelogenous leukemias [J].

Lee, JW ;

Kim, YG ;

Soung, YH ;

Han, KJ ;

Kim, SY ;

Rhim, HS ;

Min, WS ;

Nam, SW ;

Park, WS ;

Lee, JY ;

Yoo, NJ ;

Lee, SH .

ONCOGENE, 2006, 25 (09) :1434-1436

[9] A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia - The Japan adult leukemia study group AML97 study [J].

Miyawaki, S ;

Sakamaki, H ;

Ohtake, S ;

Emi, N ;

Yagasaki, F ;

Mitani, K ;

Matsuda, S ;

Kishimoto, Y ;

Miyazaki, Y ;

Asou, N ;

Matsushima, T ;

Takahashi, M ;

Ogawa, Y ;

Honda, S ;

Ohno, R .

CANCER, 2005, 104 (12) :2726-2734

[10] Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22) [J].

Nanri, T ;

Matsuno, N ;

Kawakita, T ;

Suzushima, H ;

Kawano, F ;

Mitsuya, H ;

Asou, N .

LEUKEMIA, 2005, 19 (08) :1361-1366

← 1 2 →